ROCKVILLE, Md.--(BUSINESS WIRE)--June 16, 2003--Today, Vaxim, Inc., a Rockville Maryland based biopharmaceutical company, announced that it has successfully identified and synthesized a peptide from SARS viral proteins, named V-S26, which is confirmed to bind specifically with serum antibody from SARS recovered patients. With the focus of vast amount of resources of medical and biological institutes, the immediate need of effective SARS detection, treatment and prevention solutions remain pressing concerns that have not been answered by traditional techniques. Vaxim predicts that the company's novel approach by the quick identification of peptide that interacts with antibody specific to SARS viral proteins, will...